July 6, 2022
CaaMTech Collaborates with the Alexander Shulgin Research Institute to Study Shulgin Compounds
CaaMTech will help carry on Dr. Alexander Shulgin’s legacy by developing ASRI’s novel compounds
Updates
June 15, 2022
Mike O’Shaughnessy Joins CaamTech as General Counsel and Director of Intellectual Property
O’Shaughnessy brings decades of experience in intellectual property strategy, collaborations, and development within the life sciences and pharmaceutical industries
June 2, 2022
CaaMTech Collaboration Proves Diversity in Magic Mushroom Chemistry
A new paper published by The Leibniz Institute for Natural Product Research in collaboration with CaaMTech reveals the complex chemistry of magic mushrooms
May 9, 2022
“Minor” Magic Mushroom Compound Crystal Structure Solved
CaaMTech collaborates with UMass Dartmouth to solve crystal structure of overlooked baeocystin
March 15, 2022
CaaMTech Solves Serotonin Crystal Structure
CaaMTech scientists have solved the crystal structure of freebase serotonin for the first time
February 17, 2022
Bob Discordia Joins CaaMTech as Chief Scientific Officer
Dr. Discordia brings over 30 years of pharmaceutical industry experience to CaaMTech
November 16, 2021
CaaMTech Teams Up with University of Wyoming to Study Psychedelics as Treatments for Addiction
Scientists will assess the potential of psychedelic compounds for treating addiction
September 15, 2021
CaaMTech Solves Crystalline Forms of Nine Serotonin Analogs
Serotonin is a tryptamine-based human neurotransmitter responsible for a variety of complex biological functions
September 8, 2021
CaaMTech Raises $22 Million for Psychedelic Drug Discovery and Development
CaaMTech, Inc., a leading psychedelic drug discovery company, has today announced the completion of a $22 million Series A financing …
May 3, 2021
CaaMTech CEO Chadeayne to Speak at 2021 Psychedelic Therapeutics & Drug Development Conference
Dr. Andrew Chadeayne will speak about filling the unmet need for pure, well-characterized tryptamines
